ProCE Banner Activity

Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM

Slideset Download
Conference Coverage
In this updated analysis, patients with a greater proportion of T-cells exhibiting a memory-like phenotype experienced greater CAR T-cell expansion and more durable responses.

Released: December 11, 2020

Expiration: December 10, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology